Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams acquired 48,100 shares of Vivani Medical stock in a transaction dated Friday, November 13th. The stock was acquired at an average cost of $0.99 per share, with a total value of $47,619.00. Following the completion of the transaction, the director directly owned 36,960,836 shares of the company’s stock, valued at $36,591,227.64. This trade represents a 0.13% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Vivani Medical Trading Up 2.9%
Shares of VANI stock opened at $1.05 on Wednesday. Vivani Medical, Inc. has a 1 year low of $0.80 and a 1 year high of $1.66. The firm’s fifty day simple moving average is $1.17 and its 200 day simple moving average is $1.24. The firm has a market capitalization of $94.71 million, a P/E ratio of -3.28 and a beta of 2.51.
Vivani Medical (NASDAQ:VANI – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, October 2nd. Wall Street Zen lowered Vivani Medical from a “hold” rating to a “sell” rating in a research note on Sunday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $3.75.
Get Our Latest Analysis on VANI
Vivani Medical Company Profile
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
Read More
- Five stocks we like better than Vivani Medical
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
